“Our currency is trust. One of our biggest challenges today is understanding what trust means in self-care,” stated Abbie Lennox, global head of regulatory, medical, safety & product compliance at Bayer Consumer Health.
GSCF World Congress: Supporting The Global Self-Care Agenda
Building trust, collaboration with healthcare professionals and promoting self-care in Africa were among the topics discussed during the second session on day one of the GSCF's World Congress 2022. Speakers included Bayer's Abbie Lennox, FIP's Sham Moodley and the Self-Care Trailblazer Group's Sarah Onyango
More from Policy & Regulation
• By
Energy and Commerce Health Subcommittee members, including several health care professionals, make clear their concerns about the US sunscreen market during hearing on reauthorizing FDA’s OMUFA program.
• By
Discussion of introducing additional OTC sunscreen ingredients escaped a total eclipse criticism of Trump’s health agency layoffs caused. Comments and questions by Republican members joined by several Democrats and focused testimony and answers by witnesses representing the industry and public health groups spotlighted sunscreen.
• By
Industry lobbing for pharmaceuticals to be exempt from President Trump’s sweeping US tariffs appears to have paid off.
• By
Eisai aims to support people in Japan with severe heartburn and discomfort caused by gastric acid related conditions by switching from prescription to OTC status its Pariet-branded proton pump inhibitor.
More from Health
• By
The Visby Medical Women’s Sexual Health Test is the first over-the-counter test cleared by the US Food and Drug Administration to detect chlamydia, gonorrhea and trichomoniasis. It delivers results in about 30 minutes.
• By
“I’m not sure exactly if they understood how broad this actually is and what that might potentially lead to or what the follow-up would be if somebody now decides to sell a 10-milligram version of ivermectin for human use,” says food and drug regulation attorney Frederick Stearns.
• By
Eisai aims to support people in Japan with severe heartburn and discomfort caused by gastric acid related conditions by switching from prescription to OTC status its Pariet-branded proton pump inhibitor.